PHIOGEN
A USA-based biotech housed in the Texas Medical Center’s Innovation Hub and is committed to using its breakthrough technology to deliver bacteriophage products.
PHIOGEN’s world-class patented process has received early proof of concept validation through several in vivo studies as well as use in patients under US Food and Drug Administration-approved compassionate use cases.
Latest PHIOGEN News & Features
16 October 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze